甘草酸二胺与复方甘草酸苷治疗环磷酰胺所致的药物性肝损伤患者疗效研究*

doi:10.3969/j.issn.1672-5069.2023.03.022

Abstract

Abstract: Objective The aim of this study was to compare the efficacy of glycyrrhizic acid diamine and compound glycyrrhizin in the treatment of patients with drug-induced liver injuries (DILI). Methods 97 tumor patients with DILI caused by cyclophosphamide were encountered in Nantong Tumor Hospital between July 2018 and January 2021, and were randomly divided into control group (n=47) and observation group (n=50), receiving compound glycyrrhizin or glycyrrhizic acid diamine, respectively for six months. Serum malonaldehyde (MDA), reduced glutathione (GSH), superoxide dismutase, (SOD) and advanced protein oxidation products (APOPs) levels were detected by purine oxidase; Serum interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), nitric oxide (NO) and macrophage migration inhibitory factor (MIF) levels were determined by ELISA. Results At the end of six month observation, serum bilirubin, ALT and GGT levels in the observation group were(12.3±1.5)μmol/L, (34.9±9.5)U/L and (36.9±8.8)U/L, significantly lower than [(21.7±3.1)μmol/L, (75.3±18.2)U/L and (74.2±15.2)U/L, respectively, P＜0.01] in the control; serum TNF-α, IL-6 and MIF levels were (4.1±0.8)ng/ml, (17.6±5.3)pg/ml and (6.0±0.5)ng/mL, significantly lower than [(5.9±1.2)ng/ml,(28.8±6.1)pg/ml and (10.7±0.9)ng/mL, respectively, P＜0.01] in the control group; serum MDA and APOPs levels were (4.3±0.7)μmol/L and (2.4±0.2)μmol/L, significantly lower than [(6.4±1.2)μmol/L and (4.3±0.5)μmol/L, P＜0.01], while serum SOD and GSH levels were (83.6±7.9)U/L and (7.6±1.5)μmol/L, significantly higher than [(75.2±9.2)U/L and (6.4±1.2)μmol/L, P＜0.01] in the control; at the end of one-year follow-up, 25 patients(25.8%) died of malignant tumors in our series. Conclusion The oral administration of glycyrrhizic acid diamine in the treatment of patients with DILI caused by cyclophosphamide is convenient and seems to be more efficacious compared with compound glycyrrhizin, which could improve liver function index normal and inhibit the inflammatory reactions and oxidative stress.

Key words: Drug-induced liver injury, Cyclophosphamide, Glycyrrhizic acid diamine, Compound glycyrrhizin, Therapy

Wei Dongping, Han Lili, Ling Jiahui, et al.. Efficacy of glycyrrhizic acid diamine and compound glycyrrhizin in the treatment of patients with cyclophosphamide-induced liver injury[J]. Journal of Practical Hepatology, 2023, 26(3): 388-391.

References

[1] 蔡月,邓儒,胡华斌,等. 改良剂量的FOLFOXIRI化疗方案(氟尿嘧啶、奥沙利铂、伊立替康)治疗结直肠癌的安全性和初步疗效分析. 中华胃肠外科杂志,2018,21(9):1045-1050.
[2] Devarbhavi H, Aithal G, Treeprasertsuk S, et al. Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines. Hepatol Int,2021,15(2):258-282.
[3] Li W, Li Y, Jiang X, et al. Compound ammonium glycyrrhizin protects hepatocytes from injury induced by lipopolysaccharide/florfenicol through a mitochondrial pathway. Molecules,2018,23(9):2378.
[4] Cristiano M C, Mancuso A, Fresta M, et al. Topical unsaturated fatty acid vesicles improve antioxidant activity of ammonium glycyrrhizinate. Pharmaceutics,2021,13(4):548.
[5] Li Y, Liu T, Yan C, et al. Diammonium glycyrrhizinate protects against nonalcoholic fatty Liver disease in mice through modulation of gut microbiota and restoration of intestinal barrier. Mol Pharm,2018,15(9):3860-3870.
[6] van de Sand L, Bormann M, Alt M, et al. Glycyrrhizin effectively inhibits SARS-CoV-2 replication by inhibiting the viral main protease. Viruses,2021,13(4):609.
[7] 中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南. 中华肝脏病杂志,2015,23(11):810-820.
[8] 金锐,顾红燕,李丽莉,等. LiverToX数据库收录的中草药制剂现状与分析. 中华肝脏病杂志,2016,24(11):817-823.
[9] Chen J, Huang D, She M, et al. Recent progress in fluorescent sensors for drug-induced liver injury assessment. ACS Sens,2021,6(3):628-640.
[10] Church R J, Kullak-Ublick G A, Aubrecht J, et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: an international collaborative effort. Hepatology,2019,69(2):760-773.
[11] Teschke R, Danan G. Idiosyncratic drug induced liver injury, cytochrome P450, metabolic risk factors and lipophilicity: highlights and controversies. Int J Mol Sci,2021,22(7):3441.
[12] Li F Y, Xie H, Weng L, et al. Effects of diammonium glycyrrhizinate on hepatic and intestinal UDP-glucuronosyltransferases in rats: implication in herb-drug interactions. Chin J Nat Med,2016,14(7):534-540.
[13] Yu Z, Wu F, Tian J, et al. Ammonium glycyrrhizin counteracts liver injury caused by lipopolysaccharide/amoxicillin-clavulanate potassium. Oncotarget,2017,8(57):96837-96851.
[14] Ozawa S, Miura T, Terashima J, et al. Recent progress in prediction systems for drug-induced liver injury using in vitro cell culture. Drug Metab Lett,2021,14(1):25-40.
[15] Gabora K, Piciu A, Piciu D. Drug induced liver injury to immune checkpoint inhibitors detected by F18-fluorodeoxyglucose PET/CT. J Gastrointestin Liver Dis,2021,30(2):191.
[16] Li C, Li L, Lan T. Co-treatment with disulfiram and glycyrrhizic acid suppresses the inflammatory response of chondrocytes. J Orthop Surg Res,2021,16(1):132.
[17] Yao Z, Fu Y. Glycyrrhizic acid restrains airway inflammation and remodeling in asthma via the TGF-beta1/Smad signaling pathway. Exp Ther Med,2021,21(5):461.
[18] Liu B, Gan X, Zhao Y, et al. Inhibition of HMGB1 reduced high glucose-induced BMSCs apoptosis via activation of AMPK and regulation of mitochondrial functions. J Physiol Biochem,2021,77(2):227-235.
[19] 史罗明,周根法. 阿德福韦或恩替卡韦联合甘草酸二铵治疗慢性乙型肝炎患者临床研究. 实用肝脏病杂志,2018,21(1):54-57.
[20] 刘云华,笪荣峰,徐湖波,等. 多烯磷脂酰胆碱治疗抗结核药物所致肝损伤患者疗效研究. 实用肝脏病杂志,2021,24(2):228-231.

Efficacy of glycyrrhizic acid diamine and compound glycyrrhizin in the treatment of patients with cyclophosphamide-induced liver injury

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhang Danlei, Xu Jing. Early antiviral efficacy of tenofovir amibufenamide in treatment of naïve patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(3): 336-339.
[2]	Guo Xiaoling, Zhang Yaowu, Li Mengtao, et al.. Auxiliary treatment of a herbal compound, Ganshuang granule, with entecavir for patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(3): 340-343.
[3]	Wang Yunyun, Wu Wanfeng, Li Li. Antiviral efficacy and impact on blood glucose control of direct acting antivirals in treatment of patients with genotype 1b chronic hepatitis C and type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2023, 26(3): 344-347.
[4]	Xu Haimiao, Zheng Ruiqi, Ding Huiguo. Short-term efficacy of pitavastatin and polyene phosphatidyl choline combination in the treatment of patients with nonalcoholic steatohepatitis [J]. Journal of Practical Hepatology, 2023, 26(3): 352-355.
[5]	Guo Yinyan, Yue Zhi, Gai Xiaodong, et al.. Clinical and liver pathological features of patients with autoimmune hepatitis- primary biliary cholangitis overlap syndrome [J]. Journal of Practical Hepatology, 2023, 26(3): 372-375.
[6]	Wang Junhong, Dai Ling, Chen Guobin, et al.. Cost-effectiveness analysis of reduced glutathione,diammonium glycyrrhizinate and glycyrrhizin in the treatment of patients with anti-tuberculosis medicine-induced liver injury [J]. Journal of Practical Hepatology, 2023, 26(3): 380-383.
[7]	Yang Kaining, Wang Mengmeng, Chen Xiuxiu et al.. Decreased incidences of drug-induced liver injury in patients with tubercular pleurisy and/or pulmonary tuberculosis during anti-tubercular therapy [J]. Journal of Practical Hepatology, 2023, 26(3): 384-387.
[8]	Liu Kun, Xu Jing, Ma Zhufang. Transient improvement of patients with liver cirrhosis-induced refractory ascites by oral tolvaptan administration at base of concentrated ascites reinfusion [J]. Journal of Practical Hepatology, 2023, 26(3): 396-399.
[9]	Tang Liang, Chen Xi, Wang Wengao. Short-term clinical efficacy of TACE and 3D-CRT in the treatment of patients with advanced primary liver cancer [J]. Journal of Practical Hepatology, 2023, 26(3): 416-419.
[10]	Zhang Wei, Chen Guolin, Wang Hang, et al.. Clinical feature of patients with pyogenic liver abscess with different underlying diseases [J]. Journal of Practical Hepatology, 2023, 26(3): 424-427.
[11]	Zhang Qiong, Chen Shiying, Xia Wei. Comparison of anhydrous ethanol and lauromacrogol sclerotherapy under ultrasound guidance in the treatment of patients with simple hepatic cysts [J]. Journal of Practical Hepatology, 2023, 26(3): 428-431.
[12]	Wu Zhengdong, Xu Gang, Mu Haifeng, et al.. Early LC after ERCP and EST is beneficial in the treatment of patients with simultaneous gallbladder and extrahepatic bile duct stones [J]. Journal of Practical Hepatology, 2023, 26(3): 432-435.
[13]	Zhu Ligang, Wang Tao, Zhou Weiwei, et al.. Comparison of laparoscopic hepatectomy and percutaneous transhepatic choledochoscopic lithotomy in the treatment of patients with intrahepatic bile duct stones [J]. Journal of Practical Hepatology, 2023, 26(3): 436-439.
[14]	Zhong Huan, Ye Wei. Very short-term observation of avatrombopag for the treatment of patients with liver cirrhosis and primary liver cancer and thrombocytopenia [J]. Journal of Practical Hepatology, 2023, 26(3): 440-442.
[15]	Fang Huijing, Zhu Chuanlong, Zhang Lili. Perspective on host-targeted therapeutic antiviral strategies for patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(3): 449-452.